Global Emerging Cancer Diagnostics Market Size 2016-2023

1. Global EmErGinG CanCEr DiaGnostiCs (tumor biomarkEr tEst) markEt: analysis & ForECasts, 2016-2023 (Focus on Biomarker Test Type, Application and Market Trends) 1 the research scope and methodology 1.1 scope of the report The report constitutes of an in-depth study of the global Emerging Cancer Diagnostics (Tumor Biomarker Test) market, including a thorough analysis of the product across different countries. The study also presents a detailed analysis of the market dynamics and the estimation for market size over the forecast period, 2016 to 2023. The purpose of this study on Emerging Cancer Diagnostics market is to understand prospective and current market trends at grass root level, supply and characteristics of advance cancer detection technologies, information on the end-user perception about these products and current business environment. In addition, the study also includes exhaustive information on product shortcomings, unmet needs, perception on new products, preference, competitive landscape, restrains and opportunities, and other vital information regarding different new technologies. The scope of this report is centred upon conducting a detailed study of the solutions allied with the global Emerging Cancer Diagnostics market. The market has been segmented into ‘Biomarker Test Type’, ‘Application’, and ‘Region’. Moreover, the global Emerging Cancer Diagnostics market report deliberates in detail, the analysis of all the macro & micro factors. It also evaluate the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders. • Key objectives of this research study are as following: - Identify the all market available Emerging Cancer Diagnostics Technologies in different countries Identify the current market size and future projection for Emerging Cancer Diagnostics market in different regions • 1 www.bisresearch.com  sales@bisresearch.com

2. • • • Identify the potential patient pool for Emerging Cancer Diagnostics Technologies Identify the key sources of information about Emerging Cancer Diagnostics Technologies To understand the competitive landscape in the Emerging Cancer Diagnostics market in terms of leading players To identify the role of regulatory and governmental authorities/agencies in Emerging Cancer Diagnostics market in different geographical locations To identify the geographical setting holding the largest market share in the market To gain insights in terms of current reimbursement policies, regulations, directives, laws and standards etc. in this space To understand the market dynamics (Drivers, Challenges and Opportunities) for different geographical location • • • • Report coverage of the global Emerging Cancer Diagnostics market includes key elements considered for the detailed analysis of the market: Market Overview provides an in depth analysis of the global Emerging Cancer Diagnostics market scenario, economic outlook, technology trends, and legal Requirements & Regulations Market Dynamics: Drivers, Challenges and Opportunities related to the global Emerging Cancer Diagnostics market An in-depth analysis of the different product divisions across various countries consists of valuable insights into the trend followed in the market • • • Figure 1 key Elements Considered In-Depth Market Dynamics Analysis Exhaustive Product Segmentation Comprehensive Competitive Insights Detailed Market Share Analysis Extensive Coverage of Market Players Thorough Analysis of Business Opportunities BIS Research Analysis 2 www.bisresearch.com  sales@bisresearch.com

3. The global Emerging Cancer Diagnostics market is further segmented as below: Figure 2 Global Emerging Cancer Diagnostics market segmentation FACTORS INFLUENCING CURRENT MARKET INFORMATION Key Regulatory Bodies & Patent Analysis Industry Trends Competitive Insights Compound Annual Growth Rate (CAGR) % Market Share Analysis Market Size Key Strategies and Developments Industry Analysis Market Drivers Market Opportunities Market Restraints Market Size & Forecast • By Biomarker Test • By Application • By Geography High Growth Segments Market Size Analysis KEY MARKET SEGMENTATION By Tumor Biomarker Test By Application By Geography • PSA Tests • CTC Tests • AFP Tests • CA Tests • HER2 Tests • BRCA Tests • ALK Tests • EFGR Mutation Tests • KRAS Mutation • Others • Lung Cancer • Breast Cancer • Prostate Cancer • Colorectal Cancer • Blood Cancer • Others • North America • Europe • Asia Pacific (APAC) • Rest of the World (ROW) BIS Research Analysis 1.2 bis research market research methodology The research methodology design adopted for this specific study includes a mix of data collected from primary and secondary sources. Both primary sources (in-house experts, industry leaders and market players) and secondary sources (a host of paid and unpaid databases) along with analytical tools have been used exhaustively to build the forecast and predictive models. 3 www.bisresearch.com  sales@bisresearch.com

4. Figure 3 bis research market research methodology RESEARCH APPROACH PRIMARY RESEARCH SECONDARY RESEARCH 1. DATABASE FOR KEY INDUSTRY PARTICIPANTS (DKIP) PREPARATION STUDYING THE MARKET STRUCTURE The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing directors, technology and innovation directors, and related key executives from various vendors providing technology solutions, associated service providers, and system integrators operatingin the targetedregions. E.g. CIO’s, VP, DirectorNew ProductDevelopment,Director–operations Mainly used to obtain key information about the industry’s value chain, the total pool of key players IDENTIFY MARKET, TECHNOLOGY AND COMPETITOR TRENDS 2. DISCUSSION GUIDE PREPARATION Understand market classification, and segmentation according to industry trends to the bottom-most level, regional markets, and key developments from both market- and technology-oriented perspectives A detailed questionnaire is shared with the primary respondent covering all the aspects related to the report topic 3. SCHEDULING AN APPOINTMENT Appointments are scheduled with CIO’s, VP – healthcare companies, Director with prior appointmentsand the discussionguide is shared with the primary respondentprior to the call INTEGRATE INFORMATION Integrate information within relevant documents to form launch pad for primary research 4. CALL EXECUTION A roundtable discussion is held with the KIP with the aim to gather first hand information about the technology,recent developmentsin the technologyand future outlook/ growthor decline VENDORS CONSULTANT RESELLERS 5. DOCUMENTATION POTENTIAL RESPONDENTS The interview is recorded and the information gathered in put on the drawing board with the informationcollectedthroughsecondary research. END USER MSP’s BIS Research Analysis Primary Data Sources The key data points taken from Primary Sources includes: • Validation and Triangulation of all the numbers and graphs • Validation of report segmentation and key qualitative findings • Understanding the competitive landscape • Understanding and considering the market dynamics factors for various market segment and sub-segment • Validation of impact analysis of macro and micro factors in different countries • Percentage split of individual markets for geographical analysis Secondary Data Sources The research study involves the usage of extensive secondary sources such as databases, company websites, and annual reports, among others. 4 www.bisresearch.com  sales@bisresearch.com

5. The following figure exhibits key secondary data sources considered in this report:The following figure exhibits key secondary data sources considered in this report: Figure 4 secondary Data sources STOCK ANALYST WEBSITES COMPANY SOURCES Seeking Alpha Yahoo Finance Wiki finance The Wall Street Journal Annual Reports Press Releases SEC Filings Investor Presentations Financial Disclosures SECONDARY DATA SOURCES GOVERNMENT AND REGULATORY SOURCES PUBLIC AND PRIVATE DATABASES Medline PubMed National Library of Medicine ProQuest Thin Database CMS Datasets Medicare Beneficiaries Database Oxon Epidemiology The Centre for Disease Control (CDC) The World Health Organization (WHO) The National Health Services (NHS) The National Center for Biotechnology Information (NCBI) The Food & Drug Administration of United States (U.S. FDA) BIS Research Analysis The key data points taken from secondary sources include: • Segmentation breakups, split-ups, and percentage shares • Data for market value • Key industry trends of the top players of the market • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation • Quantitative data for mathematical and statistical calculations The following figure exhibits the methodology adopted for estimating the global Emerging Cancer Diagnostics market: 5 www.bisresearch.com  sales@bisresearch.com

6. Figure 5 top Down and bottom up approach Total global Emerging Cancer Diagnostics market size ($million) Market value of global Percent split for the product type and sub-types of global Emerging Cancer Diagnostics market Emerging Cancer Diagnostics market Summation of x & y Geographical split Average selling price (ASP) for each type of product (Y) Regional and country-wise market for each sub- segment Products into number of units (X) Analysis of macro & micro factors BIS Research Analysis Note: The above approach has been followed for the market estimation of all the product segments related to Emerging Cancer Diagnostics market Having estimated the global market size, the forecast employs a set of macro factors such as the population, disease prevalence rate, population, healthcare expenditure, disposable income, and Gross Domestic Product (GDP), among others. Assumptions and Limitations The following figure exhibits the standard assumptions and limitations which have been followed throughout the research study of the global Emerging Cancer Diagnostics market: 6 www.bisresearch.com  sales@bisresearch.com

7. Figure 6 assumptions and limitations CURRENCY CONVERSION LIMITATIONS • The base currency considered for this study is U.S. $ • In the Company Profiles section, for the companies having revenues in any other currencies, is converted in to U.S. $ • The currencies other than U.S. $ are converted to U.S. $ for all statistical calculations considering the average conversion rate for the particular year • The currency conversion rate is taken from historical exchange rate of Oanda website • Technologies currently used are expected to persist through the forecast with no major breakthrough in technology • The economic downturn in future was not taken under consideration for market estimation and forecast AVERAGE SELLING PRICE (ASP) ASSUMPTION FOR MARKET ESTIMATION • The ASP is calculated for the year 2015 & 2016 and the currency considered is U.S. $ • For calculating the ASP of the market products, the weighted average of the list price of products has been considered • The base year considered for the calculation of market size was 2015. Instances where the market size for the FY 2015 were not available from primary or secondary sources, at such instances the values were estimated based on the Delphi method. • The historical year analysis was done from the FY 2010 to FY 2014 and the market size was estimated for the FY 2016 and projected from the year 2016 to 2023 BIS Research Analysis 7 www.bisresearch.com  sales@bisresearch.com

8. tablE oF ContEnts 1 the research scope and methodology 1.1 Scope of the Report 1.2 Global Emerging Cancer Diagnostics Market Research Methodology 2 introduction to Global Emerging Cancer Diagnostics market 2.1 Overview 2.2 Analysis of Lifestyle Factors 2.2.1 Obesity/Weight 2.2.2 Physical Activity 2.2.3 Food Habits 2.2.4 Alcohol & Cancer 2.2.4.1 Countries with Highest Consumption Of Alcoholic Drinks 2.2.5 Salt Consumption 2.2.6 Breastfeeding 2.3 High and Low Developed Countries 2.3.1 Men 2.3.2 Women 2.4 Data for Cancer Frequency By Country 2.4.1 Men 2.4.2 Women 2.5 Worldwide Cancer Data 2.5.1 Men 2.5.2 Women 3 market Dynamics 3.1 Market Drivers 3.1.1 Increase in Prevalence Rate Of Cancer 3.1.2 Increase in Sedentary Lifestyles 3.1.3 Robust Technological Advancement 3.1.4 Environmental Hazards 3.1.4.1 Five primary categories of carcinogens are: - 3.1.5 Government Initiatives and Investment 3.2 Market Challenges 3.2.1 High Capital Investment 3.2.2 Dearth of Skilled Professionals 3.2.3 Lack of Awareness 3.3 Market Opportunities 3.3.1 Nanotechnology Applications In Cancer 3.3.2 3D Printing In Cancer Diagnostics 3.3.3 Robotics In Cancer Diagnostics And Treatment 3.3.4 Fluid Biopsy 3.3.5 Real Time Cancer Diagnostic iKnife 4 Competitive insights Executive summary 8 www.bisresearch.com  sales@bisresearch.com

9. 5 industry analysis 5.1 5.2 6 Global Emerging Cancer Diagnostics (tumor biomarker test) market, analysis and Forecast 6.1 Assumptions & Limitations for Analysis and Forecast 6.2 Market Overview 6.3 Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test 6.3.1 Prostate Specific Antigen Tests 6.3.2 CTC Tests 6.3.3 Alpha-Fetoprotein (AFP) Tests 6.3.4 CA Test 6.3.4.1 CA 19-9 Tests 6.3.4.2 CA 125 Tests 6.3.5 HER2 Tests 6.3.6 BRCA Test 6.3.7 Anaplastic Lymphoma Kinase (ALK) Tests 6.3.8 EGFR Mutation Tests 6.3.9 KRAS Test 6.3.10 Others 6.3.10.1 National Rental Affordability Scheme (NRAS) Testing 6.3.10.2 RET Gene Testing 6.3.10.3 ROS Testing 6.3.10.4 PIK3CA Tests 6.4 Global Emerging Cancer Diagnostics Market by Application 6.4.1 Lung cancer 6.4.2 Breast cancer 6.4.3 Colorectal 6.4.4 Prostate Cancer 6.4.5 Blood Cancer 6.4.5.1 Leukaemia 6.4.5.2 Lymphoma 6.4.5.3 Myeloma 6.4.6 Others 6.5 Global Emerging Technologies in Cancer Diagnostics Market by Geography 4.1 4.2 4.3 Key Market Developments & Strategies 4.1.1 Product Launch and Development 4.1.2 Collaborations, Joint Ventures & Partnerships 4.1.3 Business Expansion and Contracts 4.1.4 Patents, Approvals and Certifications 4.1.5 Mergers and Acquisitions 4.1.6 Other Strategies Industry Attractiveness Global Market Share Analysis 4.3.1 Market Share Analysis Patent Analysis Consortiums, Associations and Regulatory Bodies 9 www.bisresearch.com  sales@bisresearch.com

10. 7 Company Profiles 7.1 7.2 7.3 7.4 6.5.1 6.5.2 6.5.3 6.5.4 North America 6.5.1.1 Europe 6.5.2.1 6.5.2.2 6.5.2.3 6.5.2.4 6.5.2.5 6.5.2.6 6.5.2.7 APAC 6.5.3.1 6.5.3.2 6.5.3.3 6.5.3.4 6.5.3.5 6.5.3.6 Rest of the World 6.5.4.1 6.5.4.2 6.5.4.3 Country Analysis 6.5.1.1.1 6.5.1.1.2 U.S. Canada Countries having the highest cancer rates Germany France The U.K. Denmark Belgium Norway India China Japan Australia Singapore Others APAC Region Middle East Africa South America Abbott Laboratories, Inc. 7.1.1 Overview 7.1.2 Financials 7.1.2.1 7.1.3 SWOT Analysis Agilent Technologies 7.2.1 Overview 7.2.2 Financials 7.2.2.1 7.2.3 SWOT Analysis AstraZeneca 7.3.1 Overview 7.3.2 Financials 7.3.2.1 7.3.3 SWOT Analysis Becton Dickinson & Co. 7.4.1 Overview 7.4.2 Financials 7.4.2.1 7.4.3 SWOT Analysis Financial Summary Financial Summary Financial Summary Financial Summary 10 www.bisresearch.com  sales@bisresearch.com

11. 7.5 7.6 7.7 7.8 7.9 7.10 7.11 7.12 7.13 Biocept Inc. 7.5.1 7.5.2 7.5.3 Cancer Genetics Inc. 7.6.1 Overview 7.6.2 Financials 7.6.2.1 7.6.3 SWOT Analysis Danaher Corporation 7.7.1 Overview 7.7.2 Financials 7.7.2.1 7.7.3 SWOT Analysis Foundation Medicine Inc. 7.8.1 Overview 7.8.2 Financials 7.8.3 SWOT Analysis Illumina Inc. 7.9.1 Overview 7.9.2 Financials 7.9.3 Financial Summary 7.9.4 SWOT Analysis LabCorp Of America Holdings 7.10.1 Overview 7.10.2 Financials 7.10.2.1 Financial Summary 7.10.3 SWOT Analysis Luminex Corporation 7.11.1 Overview 7.11.2 Financials 7.11.2.1 Financial Summary 7.11.3 SWOT Analysis Myriad Genetics Inc. 7.12.1 Overview 7.12.2 Financials 7.12.2.1 Financial Summary 7.12.3 SWOT Analysis NanoString Technologies Inc. 7.13.1 Overview 7.13.2 Financials 7.13.2.1 Financial Summary 7.13.3 SWOT Analysis Overview Financials 7.5.2.1 SWOT Analysis Financial Summary Financial Summary Financial Summary 11 www.bisresearch.com  sales@bisresearch.com

12. 7.14 7.15 7.16 7.17 7.18 7.19 7.20 Neo Genomics Inc. 7.14.1 Overview 7.14.2 Financials 7.14.2.1 Financial Summary 7.14.1 SWOT Analysis Quest Diagnostics Incorporated 7.15.1 Overview 7.15.2 Financials 7.15.2.1 Financial Summary 7.15.3 SWOT Analysis Qiagen, Inc. 7.16.1 Overview 7.16.2 Financials 7.16.3 Financial Summary 7.16.4 SWOT Analysis Roche Holding AG-BR 7.17.1 Overview 7.17.2 Financials 7.17.3 Financial Summary 7.17.4 SWOT Analysis Siemens Healthineers 7.18.1 Overview 7.18.2 Financials 7.18.2.1 Financial Summary 7.18.3 SWOT Analysis Thermo Fisher Scientific 7.19.1 Overview 7.19.2 Financials 7.19.2.1 Financial Summary 7.19.3 SWOT Analysis Snapshot of Other Key Players 7.20.1 Biotheranostics, Inc. 7.20.2 Epigenomics 7.20.3 Exact Sciences Corporation 7.20.4 Ignyta,Inc. 7.20.5 Interpace Diagnostics 7.20.6 Leica Biosystems 7.20.7 BioTime, Inc 7.20.8 Pathway Genomics 7.20.9 Sysmex Corporation 7.20.10 Almac group 7.20.11 GeneNews Limited (formerly ChondroGene Limited) 7.20.12 Rosetta Genomics 12 www.bisresearch.com  sales@bisresearch.com

13. DisClaimEr BIS Research provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer’s internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com  tel: +1 650 228 0182 16 13 www.bisresearch.com  sales@bisresearch.com